Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis Imperfecta
Clinical trial NCT05312697 · TERMINATED
Trial details
- NCT number
- NCT05312697
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-28
- Primary completion
- 2022-07-07
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.